Efficacy of Delafloxacin in Treating Community-Acquired Bacterial Pneumonia
Data support the continued study of delafloxacin as a potential treatment for community-acquired pneumonia.
|This article is part of Infectious Disease Advisor's coverage of IDWeek 2017™, taking place in San Diego, CA. Our on-site staff will be reporting on the latest breaking research and clinical advances in infectious diseases. Check back regularly for highlights from IDWeek 2017.|
SAN DIEGO —Broad-spectrum fluoroquinolone delafloxacin showed potent antibacterial activity in treating community-acquired respiratory tract infections, according to data from the SENTRY surveillance program, presented at IDWeek 2017.
Researchers from JMI Laboratories, Inc., in North Liberty, Iowa, presented data collected through the SENTRY Antimicrobial Surveillance Program from 2014 to 2016, examining the efficacy of delafloxacin in treating community-acquired respiratory tract infections.
More than 3000 isolates (n=3093) were identified between 2014 and 2016, including 1673 Streptococcus pneumoniae, 805 Haemophilius influenzae, and 555 Moraxella catarrhalis pathogens. When compared with levofloxacin and penicillin, delafloxacin “demonstrated potent in vitro activity” against S pneumoniae (minimum inhibitory concentration [MIC]50/90 0.015/0.03 mg/L); penicillin-intermediate or -resistant isolates demonstrated similar activity. Delafloxacin MIC50/90 was 0.12/0.25 mg/L among 23 levofloxacin-nonsusceptible S pneumoniae pathogens, and activity was similar among isolates in both the United States and Europe.
"The results of this survey shows that delafloxacin has potent in-vitro activity against the most common bacterial pathogens seen in community-acquired pneumonia, more potent than the other classes of antibiotics that were tested including other fluoroquinolones," said Sue K. Cammarata, MD, Melinta Therapeutics' chief medical officer, in an interview with Infectious Disease Advisor.
"We look forward to seeing the results from our phase 3 clinical trial that currently is ongoing in patients with [community-acquired bacterial pneumonia]," concluded Dr Cammarata.
All authors have received research grants from Melinta Therapeutics, Inc.
|Visit Infectious Disease Advisor's conference section for continuous coverage live from IDWeek 2017.|
Shortridge D, Streit JM, Huband MD, Rhomberg PR, Flamm RK. In vitro evaluation of delafloxacin activity when tested against contemporary community-acquired bacterial respiratory tract infection isolates (2014-2016): results from the SENTRY antimicrobial surveillance program. Presented at: ID Week 2017; October 4-8, 2017; San Diego, CA. Poster 1208.